G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference
G1 Therapeutics, a commercial-stage oncology company, announced its participation in two investor conferences in March 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics, a commercial-stage oncology company, announced its participation in two investor conferences in March 2022. On March 8, CEO Jack Bailey will join a New Drug Launches panel at the Cowen Health Care Conference. Following this, on March 15, Bailey and CMO Raj Malik will engage in a fireside chat at the Roth Conference. Both events will be accessible via webcast on the company's events page. G1 is focused on enhancing cancer treatments with its product COSELA and has a robust pipeline for various solid tumors.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was -5.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming investor conferences in March 2022.
- On Tuesday March 8, 2022, G1’s Chief Executive Officer Jack Bailey will participate in a New Drug Launches panel at 2:10PM ET during the virtual 42nd Annual Cowen Health Care Conference.
- On Tuesday March 15, 2020, Jack Bailey and Raj Malik, M.D., G1’s Chief Medical Officer, will participate in a fireside chat at 8:00AM PT during the 34th Annual Roth Conference.
The webcast and replay of both events will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.